Suven Life Sciences Limited
NSE: SUVEN · Healthcare Research, Analytics & Technology
Snapshot
Unlock Suven Life Sciences Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Suven Life Sciences Limited is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for neurodegenerative disorders. The company specialises in creating new chemical entities (NCEs) targeting central nervous system conditions such as Alzheimer's, depression, and cognitive disorders.
Business Model
The company operates as a research-intensive biopharmaceutical firm, investing in the development of proprietary drug candidates. Revenue generation is contingent upon the successful clinical advancement and eventual commercialisation or licensing of its NCE pipeline.
- Incorporation Year:1989
- Headquarters:Hyderabad, India
Management Commentary
Management focuses on advancing a diverse pipeline of clinical-stage assets targeting high-unmet-need areas in neurology and psychiatry. The company continues to prioritise R&D investment to move its therapeutic candidates through rigorous clinical trial phases.
Growth Outlook
Growth is primarily driven by the progression of clinical-stage candidates like SUVN-502, SUVN-G3031, and SUVN-911 through global regulatory milestones. Success in clinical trials and potential strategic partnerships remain the key catalysts for long-term value creation.
- Primary Focus:Central Nervous System (CNS) therapeutics
Key Risks
- Clinical Trial Failure. The company's business model is highly dependent on the success of its drug candidates in complex and lengthy clinical trial processes.
- Regulatory Risk. Failure to obtain necessary approvals from global health authorities like the FDA or EMA could significantly delay or terminate product commercialisation.
- Capital Intensity. Drug discovery requires substantial, sustained capital investment with no guarantee of future profitability or commercial success.
- Intellectual Property Risk. The company's competitive advantage relies on its ability to protect its proprietary NCEs through patents in multiple international jurisdictions.
Start your research today
Unlock AI insights, financials, peers and live data on Suven Life Sciences Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹9 Cr
TTM · consolidated
NET PROFIT
₹-352 Cr
TTM · consolidated
EPS
₹-14.89
TTM · consolidated
RETURN ON EQUITY
-100.5%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
-99.8%
TTM · consolidated
P/E
-20.7×
Q1 FY27 · consolidated
EV/EBITDA
-27.9x
Q1 FY27 · consolidated
EBITDA MARGIN
-557.4%
TTM · standalone
NET PROFIT MARGIN
-451.5%
Q1 FY27 · standalone
DEBT TO EQUITY
0.0x
Q1 FY27 · consolidated
Peers · Healthcare Research, Analytics & Technology
| Company | Mkt Cap | P/E (TTM) | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Suven Life Sciences LimitedSUVEN | ₹9,659 Cr | -20.7× | -27.94 | 17.3% | -557.4% | -100.5% | -99.8% | +48.9% |
Syngene International Ltd.SYNGENE | ₹15,414 Cr | 65.7× | 17.24 | -3.4% | 24.5% | 4.6% | 6.2% | -42.8% |
Indegene Ltd.INDGN | ₹14,419 Cr | 35.5× | 19.70 | 30.4% | 18.8% | 13.9% | 17.4% | +4.9% |
Vimta LabsVIMTALABS | ₹2,728 Cr | 32.7× | 17.34 | 15.2% | 37.3% | 19.1% | 24.1% | -18.3% |
Fabtech Technologies LimitedFABTECH | ₹661 Cr | 10.3× | 9.04 | — | 16.3% | 11.6% | 14.1% | — |
Take SolutionsTAKE | ₹235 Cr | 14.7× | 37.62 | — | 7.4% | 49.8% | 24.2% | +4.9% |
As of Q1 FY27
Financials
Suven Life Sciences Limited
NSE: SUVEN · Healthcare Research, Analytics & Technology
Snapshot
Unlock Suven Life Sciences Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Suven Life Sciences Limited is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for neurodegenerative disorders. The company specialises in creating new chemical entities (NCEs) targeting central nervous system conditions such as Alzheimer's, depression, and cognitive disorders.
Business Model
The company operates as a research-intensive biopharmaceutical firm, investing in the development of proprietary drug candidates. Revenue generation is contingent upon the successful clinical advancement and eventual commercialisation or licensing of its NCE pipeline.
- Incorporation Year:1989
- Headquarters:Hyderabad, India
Management Commentary
Management focuses on advancing a diverse pipeline of clinical-stage assets targeting high-unmet-need areas in neurology and psychiatry. The company continues to prioritise R&D investment to move its therapeutic candidates through rigorous clinical trial phases.
Growth Outlook
Growth is primarily driven by the progression of clinical-stage candidates like SUVN-502, SUVN-G3031, and SUVN-911 through global regulatory milestones. Success in clinical trials and potential strategic partnerships remain the key catalysts for long-term value creation.
- Primary Focus:Central Nervous System (CNS) therapeutics
Key Risks
- Clinical Trial Failure. The company's business model is highly dependent on the success of its drug candidates in complex and lengthy clinical trial processes.
- Regulatory Risk. Failure to obtain necessary approvals from global health authorities like the FDA or EMA could significantly delay or terminate product commercialisation.
- Capital Intensity. Drug discovery requires substantial, sustained capital investment with no guarantee of future profitability or commercial success.
- Intellectual Property Risk. The company's competitive advantage relies on its ability to protect its proprietary NCEs through patents in multiple international jurisdictions.
Start your research today
Unlock AI insights, financials, peers and live data on Suven Life Sciences Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹9 Cr
TTM · consolidated
NET PROFIT
₹-352 Cr
TTM · consolidated
EPS
₹-14.89
TTM · consolidated
RETURN ON EQUITY
-100.5%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
-99.8%
TTM · consolidated
P/E
-20.7x
Q1 FY27 · consolidated
EV/EBITDA
-27.9x
Q1 FY27 · consolidated
EBITDA MARGIN
-557.4%
TTM · standalone
NET PROFIT MARGIN
-451.5%
Q1 FY27 · standalone
DEBT TO EQUITY
0.0x
Q1 FY27 · consolidated
Peers · Healthcare Research, Analytics & Technology
As of Q1 FY27